Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/detail.php on line 234

Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 82

Warning: array_push() expects parameter 1 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 85
Pharmalicensing | Life Science's Global Technology Marketplace
Save this technology
close
Save to Existing Project
Save to a New Project
Diagnostic Kit/antibody for Acute Myocardial Infarction_SJ BIOMED Inc.
Korea Health Industry Development Institute (KHIDI) South Korea flag South Korea
Abstract ID:
Diagnostic kit/antibody for Acute Myocardial Infarction...
Contact Yong U Kim
Participants
You
Email me a copy of this message

NCM test is an immunoassay for the rapid qualitative detection of NCM in human whole blood or serum at a cut off level of 0.5ng/ml. With heart tissue specificity and accuracy with high sensitivity as early as 2 hr after the onset, it may provide an aid in the diagnosis of myocardial infarction in emergency room. Further quantitative and qualitative study in patients will provide more information ensuring that NCM test may enable physician to decide whether patients can be replaced in thrombolytic therapy or not.


-          Diagnosis kit : detection sensitivity needs to be increased further


-          Antibody: best pairing process for best quantification


-          Human data needs to be acquired to confirm our hypothesis and rationale


NCM test is an immunoassay for the rapid qualitative detection of NCM in human whole blood or serum at a cut off level of 0.5ng/ml. With heart tissue specificity, sensitivity, accuracy as early as 2 hr after chest pain and assay read time 15 minutes, it may provide an aid in the diagnosis of myocardial infarction less than 6hr in emergency department. Further quantitative and qualitative study in patients will provide more information ensuring that NCM test may enable physician to decide whether patients can be placed in thrombolytic therapy or not.

GO PREMIUM TO GET PATENT INFORMATION
Type of Business Relationship Sought
US7514227B2, EP1165133 B1, NK1049121, CA2366468A1, CA2366468C, CN1368888A, CN1368888B, DE60045444D1, EP1165133A1, EP1165133A4, US20070122846, WO2001058482A1
FEATURED
Last Updated Jun 2016
Technology Type DIAGNOSTIC
Phase of Development EARLY STAGE
GOVERNMENT INSTITUTE